The adult blood-brain barrier, unlike the neonatal blood-brain barrier, does not transport lysosomal enzymes into brain, making enzyme replacement therapy ineffective in treating the central nervous system symptoms of lysosomal storage diseases. However, enzyme transport can be re-induced with alpha-adrenergics. Here, we examined agents that are known to alter the blood-brain barrier transport of large molecules or to induce lysosomal enzyme transport across the blood-brain barrier ((AE)epinephrine, insulin, retinoic acid, and lipopolysaccharide) in 2-week-old and adult mice. In 2-week-old adolescent mice, all these pharmacologic agents increased brain and heart uptake of phosphorylated human b-glucuronidase. In 8-week-old adult mice, manipulations with (AE)epinephrine, insulin, and retinoic acid were significantly effective on uptake by brain and heart. The increased uptake of phosphorylated human b-glucuronidase was inhibited by mannose 6-phosphate for the agents (AE)epinephrine and retinoic acid and by L-NG-nitroarginine methyl ester for the agent lipopolysaccharide in neonatal and adult mice. An in situ brain perfusion study revealed that retinoic acid directly modulated the transport of phosphorylated human b-glucuronidase across the blood-brain barrier. The present study indicates that there are multiple opportunities to at least transiently induce phosphorylated human b-glucuronidase transport at the adult blood-brain barrier.
Introduction
Lysosomal storage diseases (LSDs) are hereditary disorders that are characterized by metabolic abnormalities caused by enzymatic dysfunction in lysosomes. 1, 2 Most of the LSDs are caused by the lack of one of the lysosomal hydrolases, a group of enzymes involved in the metabolism of glycoproteins, sphingolipids, and glycosaminoglycans and whose absence results in diverse clinical manifestations. The symptoms of LSDs are commonly progressive in the central nervous system (CNS) and peripheral organs, leading to early death. 1, 2 Enzyme replacement therapy (ERT) by the intravenous route is effective in improving symptoms in peripheral organs, 2, 3 but has limited effects on the CNS because the blood-brain barrier (BBB) blocks access of the lysosomal enzyme to brain.
In our prior studies, 4, 5 we discovered that luminally expressed cation-independent mannose 6-phosphate (CI-M6P) receptor is a transporter at the neonatal BBB for lysosomal enzymes that contain M6P moieties. The presence of this transporter allows parenterally administered enzyme to access the neonatal brain in therapeutic amounts. 6, 7 receptor-dependent transport becomes inactive with development and so is not available to deliver lysosomal enzymes across the adult BBB. 4, 5 Conceptually, if one can re-induce CI-M6P receptor-mediated transport of lysosomal enzymes in adult BBB, this strategy could provide a novel brain targeting approach for treating abnormal storage in the CNS regardless of the age of subjects. We previously showed that systemic epinephrine restored CI-M6P receptor-mediated transport of recombinant phosphorylated human b-glucuronidase (P-GUS) across the adult BBB. 8 Recently, adrenergic stimulation was found to improve the therapeutic CNS outcome of lysosomal ERT in an animal model of Pompe disease, another disease in which enzyme delivery is dependent on the CI-M6P receptor. Interestingly, there is accumulating evidence indicating that some lysosomal enzymes may employ multiple mechanisms for their transport across the BBB. 10 For example, arylsulfatase A employs both CI-M6P receptor transport and adsorptive transcytosis in an in vitro model of the BBB. 11 The mechanism of adsorptive transcytosis is most likely to occur at high doses of ERTs, including mucopolysaccharidoses, 6, 12, 13 aspartylglucosaminuria, 14 metachromatic leukodystrophy, 15 and a-mannosidosis. 16, 17 This suggests that if circulating levels of lysosomal enzyme can be maintained at high levels for a long time, the availability of the enzyme to be delivered into the CNS increases in some LSDs.
In the present study, we have further investigated systemic responses to pharmacologic stimuli of known BBB transport mediators on the induction of M6P receptor-mediated and/or adsorptive-mediated transport processes in the BBB. Pharmacological agents for macromolecule transport across the BBB include (AE) epinephrine, insulin, retinoic acid, lipopolysaccharide (LPS). The mechanisms of induced transport were investigated by inhibition studies with M6P and L-NG-nitroarginine methyl ester (L-NAME).
We used P-GUS as a model lysosomal enzyme to be delivered into the brain. We here report evidence that multiple mechanisms can enhance the delivery of P-GUS into the brain by manipulating endogenous characteristics of the BBB.
Materials and methods
Production of recombinant human lysosomal enzymes P-GUS was produced in overexpressing, CI-M6P receptor-deficient mouse L cells as described in Grubb et al. 18 The enzyme was purified from conditioned media by anti-human GUS mAb affinity column chromatography. P-GUS was eluted with 3.5 M MgCl 2 , then desalted over Bio Gel P6 sizing resin (Bio-Rad, Hercules, CA). Recombinant non-phosphorylated human GUS (NP-GUS) was produced in Sf21 insect cells by using the baculovirus system as described for mouse GUS. 19 The concentration of the P-GUS was adjusted to 2.5 Â 10 5 units per mL (1 unit ¼ 1 nmol of substrate cleaved per hour), and both purified enzymes were stored at À70 C. M6P-specific uptake of the P-GUS purified enzymes by human fibroblasts was 185 units per mg/h, respectively (data not shown).
Radioactive labeling
P-GUS and NP-GUS were radioactively labeled using the iodobead method (Pierce, Rockford, IL) with [ 131 I]Na (Perkin Elmer, Waltham, MA), as we reported earlier in the context of labeling GUS. The use of a single iodobead allows controlled iodination, so that both enzymatic activity and susceptibility to endocytosis by the M6P receptor are preserved. 4, 5, 8 Labeled, active enzyme was separated from free iodine on a Sephadex G-10 column. Albumin was labeled with [ 125 I]Na (Perkin Elmer) using the chloramine-T method and purified on a column of Sephadex G-10. Each reagent was freshly prepared on the day of the experiment.
Animals
Male CD-1 mice from our in-house colony were studied at two days (0.8-1.3 g), two weeks (4.2-5.5 g), and 7-8 weeks (19.0-26.2 g) of age. The mice had free access to food and water and were maintained on a 12-h dark/light cycle in a room with controlled temperature. The studies were carried out in accordance with the recommendations in the guide for the Care 5 cpm of each) into the superficial temporal vein (neonates) or jugular vein (adults). At designated times from 1 to 10 min after the injection, mice were sacrificed under anesthesia, and the blood, brain, and heart were collected immediately. Serum from mouse blood was isolated by centrifugation. To modulate brain uptake of [ 131 I]P-GUS following pharmacologic agents were i.v. co-injected; racemic (AE)epinephrine (1.6 mmol/kg), M6P (2 mmol/injection), insulin (20 mmol/kg), and retinoic acid (0.01-10 nmol/injection). Due to poor water solubility of retinoic acid, the i.v. dose was not strictly proportional to the body weight of mice. The concentration of retinoic acid in injection solution was at 5.2 nmol/100 mL. However, graded-dosing of retinoic acid was given in neonate to adult mice with the limitation of the volume of injection up to 10 mL in neonates and 200 mL in adults not to complicate vascular volume in mice. LPS (3 mg/kg) was injected three times with 10 min interval 30 min prior to the injection of [ 131 I]P-GUS, and L-NAME (10 mg/kg) was injected i.v. 30 min prior to the treatment with LPS. All reagents were from commercial sources. The doses of these agents were determined on the basis of data from our prior studies or established doses from representative pharmacologic studies. [20] [21] [22] [23] [24] In situ transcardiac brain perfusion
Mice at the age of two weeks were anesthetized with 40% urethane, the heart exposed, both jugulars severed, and the descending thoracic aorta ligated. A 26-gauge butterfly needle was inserted into the left ventricle of the heart, and the perfusion fluid, containing [
131 I]P-GUS and [
125 I]albumin with or without retinoic acid (3 M), was infused at a rate of 2 mL/min for 1, 3, or 5 min. After perfusion, the whole brain was removed and weighed. The level of radioactivity was determined in a g-counter.
[
131 I]P-GUS (200,000 cpm/ mL) with or without retinoic acid was diluted in prewarmed physiological buffer (7.19 
Evaluation of tissue uptake
The brain/serum, tissue/serum, or brain/perfusion ratios for [
I]P-GUS and [
125 I]albumin were calculated by dividing the radioactivity in a gram of brain by the radioactivity in a milliliter of serum, having a dimension of the volumes of distribution in brain.
To estimate the blood-to-brain unidirectional influx rate (K in ) of radioactively labeled agents in the in situ perfusion study, the brain/perfusion ratios were plotted against perfusion time T in min using the following equation.
where Am and Cp are the cpm/g of brain and the cpm/mL of perfusion fluid at time T, respectively. Kin was measured as the slope for the linear portion of the relation between the brain/perfusion ratios and respective perfusion time T. The y-intercept of the line represents V i , the distribution volume in the brain at T ¼ 0.
Brain clearance study
Brain clearance was measured as previously described in Banks et al. 25 Mice at the age of 7-8 weeks old received an intracerebroventricular (i.c.v.) injection of [ 
where m is the slope and i is the y-intercept of the line.
Statistical analysis
The mean values are presented with their SEs and compared by one-way analysis of variance followed by Dunnet's or Newman-Keuls multiple comparison tests, or by two-tailed unpaired t test for linear regression results using the Prism 5.0 program (GraphPad Inc, San Diego, CA).
Results

Manipulation of brain uptake of -glucuronidase by endogenous characteristics of the BBB
We studied the acute effects of pharmacological manipulations on [ 131 I]P-GUS delivery into brain using known modulators of macromolecule transport across the BBB, including (AE)epinephrine, insulin, retinoic acid, and LPS. Doses of these agents were based on previous studies. [20] [21] [22] [23] [24] [ 131 I]P-GUS transport across the BBB was measured in mice at the ages from 2 to 8 weeks, the time period when mice gradually lose the functional transport of lysosomal enzymes mediated through the CI-M6P receptor at the BBB. 4 ]albumin levels also suggests that the integrity of the BBB was not altered by these pharmacological manipulations. The increases in net uptake of [
131 I]P-GUS in brain in 2-and 8-week-old mice were 1.4-2.0 fold for insulin and 2.4-2.9 fold for (AE)epinephrine, compared to those in untreated age-matched control mice. Increased uptake was also observed in the heart where insulin increased the net uptake 1.5-1.6 fold and the increase for (AE)epinephrine was 3.9-4.5 fold in neonatal and adult mice. Epinephrine-induced uptake of [ 131 I]P-GUS in the brain and heart in adult mice was inhibited by M6P ( Figure 1 ) which was consistent with our prior study. 8 Next, we tested the effects of LPS and L-NAME on brain uptake of [ 131 I]P-GUS ( Figure 2 ). LPS treatments significantly increased brain and heart uptakes of [ 131 I]P-GUS 10 min after injection of [ 131 I]P-GUS in 2-week-old mice. LPS-induced tissue uptake of [ 131 I]P-GUS was significantly inhibited by L-NAME injected 30 min prior to LPS dosing, suggesting that the increased tissue uptake of [
131 I]P-GUS by LPS was mediated through nitric oxide activity. However, these effects on [
131 I]P-GUS uptake were not observed in adult mice. Neither of these two agents affected vascular spaces ([ 125 I]albumin) in the brain and heart, regardless of the age of mice. Similar results although less robust were obtained with sulfamidase (data not shown), suggesting these agents work on other lysosomal enzymes.
Retinoic acid enhanced brain uptake of -glucuronidase
Brain endothelial cells highly express retinoic acidinduced transcriptomes, 26 and retinoic acid has diverse (d) show that brain-and heart-to-serum ratios in 8-week-old mice, respectively. Values are expressed as mean AE SE of 8-10 determinations. Oneway ANOVA followed by Dunnet's post hoc test was employed for statistical evaluation. Asterisks show that statistical difference from control values, *P < 0.05, **P < 0.01, and ***P < 0.001. biologic effects on cellular functions. For example, retinoic acid promotes intracellular redistribution of CI-M6P receptors. 27 ,28 Thus, we tested the effect of retinoic acid on brain uptake of P-GUS in neonate and adult mice. Figure 3 shows the distribution of 131 I]P-GUS levels were significantly increased by M6P (2 mmol per mouse), implying that retinoic acid-induced uptake of [
131 I]P-GUS by brain and heart is mediated through CI-M6PR. Dose-dependency in [
131 I]P-GUS uptake was not observed in 8-week-old mice, but retinoic acid at the highest dose (10 nmol) significantly increased [
131 I]P-GUS uptake both in the brain and heart, and such increases in tissue uptake were higher than respective vascular spaces in these tissues.
Retinoic acid directly interacted with the BBB to increase brain uptake of -glucuronidase from vasculature ]albumin with or without retinoic acid goes directly to the cerebral vasculature, negating first pass effects through lung or liver as well as peripheral factors such as binding proteins which may interact with the substance of interest and so alter its BBB transport. We used serum-free artificial perfusion fluid both to negate the interaction of study substances with blood components and also to limit the site of action for P-GUS uptake by retinoic acid at the cerebral vasculature. In a prior study, the transport of P-GUS was ) show that brain-and heart-to-serum ratios in 2-week-old mice, respectively. Panels (b) and (d) show that brain-and heart-to-serum ratios in 8-week-old mice, respectively. Values are expressed as mean AE SE of 5-8 determinations. One-way ANOVA followed by Dunnet's post hoc test was employed for statistical evaluation. Asterisks show that statistical difference from control values, *P < 0.05 and **P < 0.01. not detected in adult mice by the in situ brain perfusion method. 4 However, we found that 2-week-old mice retained active transport of [ 131 I]P-GUS at the BBB in the present study (Figure 4 ). While [
131 I]P-GUS was transported across the BBB at the influx rate of 3.76 AE 0.71 mL/g/min in 2-week-old mice, retinoic acid at 3 M significantly increased the influx rate of 131 I]P-GUS levels in the brain, heart, and serum by retinoic acid treatment. Tissue-to-serum ratios of [ 131 I]P-GUS in the brain (a), heart (b), and serum (c) after i.v. co-injection with retinoic acid in 2-day-old mice. Brain (panels (d) and (f)) and heart (panels (e) and (g)) uptakes of [ 131 I]P-GUS in 2-and 8-week-old mice are shown, respectively. Each column represents mean AE SE of 4-13 determinations. The dashed line represents tissue vascular space simultaneously measured by [
125 I]albumin co-injection. One-way ANOVA followed by Dunnet's post hoc test was employed for statistical evaluation among control and retinoic acid treated groups. A two-tailed unpaired t test was used to compare the highest concentration of retinoic acid and M6P treated groups. Asterisks show a statistical difference from control values, *P < 0.05 and **P < 0.01. Daggers show a statistical difference between the groups receiving retinoic acid (1 nmol/injection) and retinoic acid with M6P (2 mmol/injection), yyyP < 0.001.
Brain clearance of -glucuronidase was non-specific and independent from its phosphorylation state
To investigate subarchinoidal clearance of GUS by the bulk flow of CSF, 29 we further investigated the clearance of P-GUS and NP-GUS after i.c.v. injection into the lateral ventricle in adult mice at the age of 7-8 weeks. Either ]albumin were identical, suggesting that there was no phosphorylation state dependency in CSF clearance and that no measurable active elimination mechanism for GUS from CSF compartment, such as albumin, is cleared from brain by the mechanism of bulk flow.
Discussion
The difficulty in delivering lysosome enzymes across the BBB has been a pivotal issue in the treatment of the CNS component of LSDs. This is due to the lack of universal methodologies for CNS delivery of therapeutic molecules and incomplete understanding of CNS barriers. In our previous studies, 4, 5 we have characterized the mechanisms of BBB transport for lysosomal enzymes using the enzyme P-GUS which was resistant to metabolism and retained enzymatic activities during the course of brain uptake. Although the half-life of P-GUS in the systemic circulation is about 5 min, this short half-life is mainly mediated by peripheral tissue sequestration, not by degradation in the blood stream. 30, 31 This metabolically stable feature of P-GUS aids in studies of its pharmacological manipulations. In earlier studies, we also measured the half-life of GUS in brain and found it to be 4.5 days, suggesting that GUS activity lasts a long time once it gets in brain. 32 In the present study, we further investigated pharmacological manipulations for brain delivery of intravenously administered P-GUS into adult brain. Pharmacologic agents for the manipulation of BBB transport include (AE)epinephrine, retinoic acid, insulin, and LPS. The doses of pharmacologic agents were determined based on our prior studies testing their effect on BBB permeation. 8, [20] [21] [22] [23] [24] Although it is known that the injection of epinephrine transiently increases systemic blood pressure, the dose (1.6 mmol/kg) of epinephrine used in this study did not compromise the integrity of the BBB in vivo as seen in our previous study. 8 LPS (3 mg/kg) potentially increases a vascular permeability in the brain and periphery and would produce sickness behavior. Insulin (20 mmol/kg) could induce hypoglycemia.
We used the endogenous characteristics of the BBB to induce brain uptake of a lysosomal enzyme into the adult mouse and addressed potential mechanisms of the induction of transport across the BBB.
First, we confirmed that radioactively labeled P-GUS retained saturable transport properties which are re-inducible by the pharmacologic agent (AE)epinephrine as seen in prior study. 8 Thus, we could use epinephrine-induced uptake of P-GUS as a reference for restored transport activity both in the CNS and peripheral tissue. We showed the successful re-induction of CI-M6P receptor-mediated transport for [ 131 I]P-GUS in the brain and heart in 2-and 8-week-old mice. In related experiments, Koeberl et al. 9 recently showed enhanced uptake of activity of acid alphaglucosidase by chronic treatment with adrenergic agents in the brain and muscle, and also found that the effect of b 2 -adrenergics in enhancing the efficacy of the ERT in Pompe disease model mice was, at least in part, mediated through adrenergic-induced, increased expression of CI-M6P receptors in the brain. There was about a 1.4-fold increase in the CI-M6P receptor level by clenbuterol in the cerebellum. Adrenergic receptors are G protein-coupled receptors which participate in numerous signal transduction pathways as well as change the functionality of the surface membrane in endothelial cells. Brain microvessel endothelial cells forming the BBB express both alphaand beta-adrenergic receptors at the lumen. In an early study, adrenergic receptors participated in regulation of barrier function as well as promoted pinocytotic activity at endothelial cell surfaces. 33, 34 Internalization of adrenergic receptors through the turnover of endocytic vesicles was initially studied as a mechanism of desensitization, which leads to either short-term recycling of receptors or long-term down-regulation by the decrease of the receptor population. The increase in the rate of cell surface receptor disappearance by endocytic vesicles shows the changes in vesicular translocation and activity which is induced by the ligands. In our prior study, we demonstrated that the epinephrine-induced brain uptake of P-GUS in adults was CI-M6P receptor-mediated transport. 8 The stimulated uptake of GUS showed that a dependence on phosphorylation, thus indicating M6P moieties on the enzyme GUS regulates the transport, and that epinephrine-induced P-GUS uptake in brain was completely inhibited by co-injection of M6P in a dose-dependent manner. 8 That study also suggested that loss of functional transport across the adult BBB of lysosomal enzyme by CI-M6P receptor could be partially reversed by change in intracellular distribution of the receptor, as it was too rapid (10 min) to reflect new synthesis of receptor at the plasma membrane surface in brain microvessel endothelial cells.
Retinoic acid plays important biological roles that include regulation of cellular functions. For example, brain tissue contains cellular retinol-binding proteins and a nuclear receptor protein for retinoic acid. Cellular retinol-binding protein was localized to brain microvessel endothelial cells and to the choroid plexus epithelial cell layers. A transcriptome study of the BBB showed that the RXR alpha signaling cascade is specifically enriched in the brain microvessel endothelial cells. 26 Retinoic acid promotes intracellular redistribution of CI-M6P receptors which are detected in endosomes, in the trans Golgi element, and at the plasma membrane in varying proportions in different cell types. 27, 28 In this study, we measured retinoic acidinduced brain uptake of [
131 I]P-GUS in neonates and adults. The magnitude of increase in brain [
131 I]P-GUS uptake by retinoic acid decreased with maturation regardless of a substantial increase in doses of retinoic acid. However, an increase in [
131 I]P-GUS uptake by brain and heart did occur and was M6P sensitive. Considering the fact that retinoic acid is known to induces relocation of intracellular CI-M6P, we propose that the retinoic acid-induced [ 131 I]P-GUS uptake was mediated through a CI-M6P receptor-mediated process that resulted from redistribution of CI-MPR to the luminal surface of brain microvessel endothelial cells (Figure 4) . Furthermore, retinoic acid did not change brain vascular space, suggesting that increased brain uptake of [ 131 I]P-GUS was not due to a compromise in the barrier integrity. In addition, cation-dependent M6P receptor does not bind M6P at neutral pH, suggesting physiologic pH7.4 only allows CI-M6P receptors to be responsible for P-GUS uptake. 35, 36 Currently, the mechanisms of action for brain uptake of [ 131 I]P-GUS by insulin and LPS remain speculative. The insulin receptor belongs to the receptor tyrosine kinase family which has endothelial nitric oxide synthase (NOS) as its downstream signal transduction. Insulin in the CNS is neuroprotective and retains many of its ancient growth hormone-like properties. 37 It is well known that ligand binding to the receptor tyrosine kinases promotes internalization of the activated receptors through clathrin-dependent or caveolae-mediated pathways which modulate the intracellular vesicle activity and re-localization. 38 Also, LPS is a potent inducer of NOS activity and L-NAME is a specific inhibitor of NOS. Nitric oxide (NO) can influence vesicle activity and re-location processes, and NO directly stimulates insulin transport in vascular endothelial cells. 39 One of our prior studies showed that LPS affects insulin transport across the BBB by modulating NOS isozyme activity. 23 NO released by endothelial NOS and inducible NOS acts to stimulate insulin transport. Considering the increased brain uptake of [
131 I]P-GUS by insulin and LPS (Figures 1 and 2 ), endocytic activity stimulated by these agents may enable either receptor-or adsorptive-mediated cellular uptake of [ 131 I]P-GUS at luminal surface of brain microvessel endothelial cells which may be mediated through the changes in intracellular vesicle activity and re-localization of CI-M6P receptors. 40 It is of interest that epinephrine and insulin affected both adolescents and adults, while LPS had a detectable effect only in adolescents in this single dose study. Figure 6 illustrates some of the complexities of the induction of vesicular transport at the BBB. Epinephrine-induced brain uptake of [ 131 I]P-GUS was mediated through coordinated stimuli of adrenergic receptors as a nature of (AE)epinephrine binding to receptor subtypes. Retinoic acid directly interacts with the brain microvasculature and retinoic acid-induced brain uptake of [
131 I]P-GUS was M6P sensitive, suggesting the restoration of CI-M6P receptor-mediated uptake processes across the BBB. Our results suggest that insulin and LPS also contribute to [
131 I]P-GUS uptake by brain. While we conducted in vivo determinations of transport mechanisms for [ 131 I]P-GUS, one clear finding in the present study is that there are Figure 6 . Schematic presentation of pharmacologic inductions of P-GUS transport across adult BBB. Epinephrine-induced brain uptake of P-GUS was mediated through coordinated stimuli of adrenoceptors. Insulin and LPS also contribute P-GUS uptake by brain. Retinoic acid directly interacts with brain microvasculature and retinoic acid-induced brain uptake of P-GUS was M6P sensitive, suggesting the restoration of M6P receptor-mediated uptake process across the BBB. multiple opportunities to induce the transport at the adult BBB by modulating endogenous mechanisms. Further studies confirming the effectiveness of these pharmacological manipulations in higher vertebrates are needed. Also, chronic multiple dosing studies such as those of Koeberl et al. 9 are necessary to determine which of these pharmacological manipulations might potentially have clinical application to enhancing enzyme delivery to brain.
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